Biolab Sanus Farmaceutica

Biolab Pharma at a Glance: (1) Biolab is a 100% Brazilian pharmaceutical company focused on prescription products. (2). The company is ranked as the #3 largest sales force in the Brazilian Market, with 1,600 sales reps that visit over 320,000 doctors monthly. (3). We are among Brazil's top 10 pharmaceutical companies in sales in just 25 years of history. (4). For FY2023 is expected annual gross revenue of ~500MM. Ranked #5 prescription pharma. (5). Leading pharmaceutical private company in Brazil in sales and prescription in the cardiology field. (6). We have an extensive and robust portfolio in dermatology, gastroenterology, pediatrics, and central nervous system segments. (7). The company has over 3,500 fully dedicated employees to work with innovation from the operation to the top management. (8). We have high development capacity, state-of-the-art facilities with 4 manufacture sites, 3 R&D centers in Brazil, continuously invests in developing innovative products. (9). Biolab counting on promising R&D in Canada with various "me better" products based on differentiated technology platforms. (10). Innovation is the DNA of the company. Biolab is looking for partners that expect the best-in-class go-to-market for innovative products. (11). Biolab seeks distribution rights for Brazil and for some selected LATAM markets by financing other life sciences companies in the late stage, aiming to have life-enhancing and affordable products for patients. (12). We are interested in strategic and exclusive prescription products based on Radical and Incremental innovation (me better) with proven clinical trials and late-stage drug discoveries (Phase III). (13). The company has over 50 international partnerships of products from in-licensing deals ongoing with global pharma companies, such as Eli Lilly, Amgen, Takeda, Novartis, Ferring, Faes Pharma, Menarini, Kowa, among others.